You can buy or sell Celyad and other stocks, options, ETFs, and crypto commission-free!
Celyad SA American Depositary Shares, also called Celyad, is a clinical-stage biopharmaceutical company, which engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. Read More The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
Mont-Saint-Guibert, Walloon Region
52 Week High
52 Week Low
Celyad Announces First Quarter 2019 Financial Results and Recent Business Highlights
MONT-SAINT-GUIBERT, Belgium, May 09, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced an update on operational developments for the first quarter ended March 31, 2019. "We began the year with the announcement that treatment with CYAD-01 demonstrated a 40% complete response rate in patients with relapsed/refractory acute myeloid leukemia. As we continue to advan...
Yahoo FinanceMay 2
Celyad Announces May 2019 Investor Conference Schedule
MONT-SAINT-GUIBERT, Belgium, May 02, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that management plans to attend the following events in May 2019: Conference details: 5th Annual SunTrust Robinson Humphrey (STRH) Life Sciences Summit Date: Wednesday, May 8, 2019 Location: New York, NY CAR-T and The Rise of the Cellicon Valley Date: Friday, May 10, 201...